burn wound infection was initially described by Scott and colleagues1 over four decades ago. A 2-year-old girl burned her finger on a cigarette and the area was kissed by her mother, who had a history of orolabial herpes. Although the burn appeared to heal, it became blistered 2 days after the injury, and vesicular lesions developed along the hand and arm, from which herpes simplex virus (HSV) (2) decreased T-lymphocyte counts with reduced T-helper:T-suppressor ratios and percentages of helper T cells;8'9 (3) decreased in vitro lymphocyte responsiveness to mitogenic and HSV antigenic stimuli;'0 (4) decreased T-lymphocyte production of interleukin-2 (IL-2);"1"2 (5) decreased natural killer (NK) cell cytotoxicity;13 and (6) diminished antibody-dependent cellular cytotoxicity to HSV-infected cells. '4 In general, the magnitude and duration of these abnormalities appear to be related to the severity of the burn. In more severe burns, alterations in T-lym-
erpetic burn wound infection was initially described by Scott and colleagues1 over four decades ago. A 2-year-old girl burned her finger on a cigarette and the area was kissed by her mother, who had a history of orolabial herpes. Although the burn appeared to heal, it became blistered 2 days after the injury, and vesicular lesions developed along the hand and arm, from which herpes simplex virus (HSV) was isolated. This case probably represented a primary herpetic whitlow developing in a thermally injured area, and indeed herpetic lesions occurred several times thereafter at the original site of the burn.
Several decades later, the problem of herpesvirus infections in burn victims was noted again, this time by health-care workers at the Brooke Army Medical Center. In a retrospective study, Nash However, to our knowledge, the possible clinical value of administering such cytokines has not been studied in controlled trials.
HSV INFECTIONS
Few longitudinal studies on the frequency of laboratory-documented HSV infections have been reported in burn patients (Table 1) .1051-7 Although some studies have relied solely on serologic monitoring, which can be confounded by assay insensitivity, inadequate humoral immune responses, incomplete follow-up, and transient antibody rises due to passive transfer from blood products support, these studies have found that one fourth or more of burn patients have evidence of HSV infection. Virus isolation from oropharyngeal secretions, a marker of active virus replication, has been found in 10 percent to 29 percent of patients in whom serial samples have been collected (Table 1) . One study17 of patients without evident burn wound involvement found that the risk factors for serologically documented HSV infection were facial burn (59 percent infected in those with vs 20 percent infected in those without), inhalation injury (64 percent vs 12 percent), endotracheal intubation (58 percent vs 0 percent), full-thickness burn (50 percent vs 0 percent), hospitalization greater than 3 weeks (50 percent vs 0 percent), and age of 50 years or older (75 percent vs 30 percent). Although this study did not find differences in the frequency of infection in seropositive and seronegative patients based on initial complement fixation antibody titers, the observation that severe burns involving the face and upper respiratory tract are commonly associated with HSV infection provides some evidence that reactivation of infection is occurring in many patients.
The manifestations of HSV infection in burn patients range widely from the relatively common occurrence of asymptomatic shedding, to typical recurrent orolabial disease, to apparently infrequent instances of burn wound infection, to rare cases of visceral dissemination recognized only at autopsy. Because HSV can invade burned areas and produce erosive lesions that may be difficult to distinguish from the original wound, problems with recognition and underreporting are likely. Clinically apparent disease appeared to be uncommon in the reported series ( Table 1 and in one instance, DNA restriction endonuclease studies indicated that two HSV strains were identical, suggesting that nosocomial cross-infection had occurred. 25 More than 90 percent of studied cases have been associated with fever, and lesions have usually been detected between 1 and 3 weeks following the initial burn (Table 3) . Although the onset of lesions averaged 15 days following the burn, some cases occurred within the first week and approximately one quarter occurred after 3 weeks. Concurrent active orolabial herpes has been described in a minority of patients but is probably both underrecognized and underreported. Areas of active epidermal regeneration are most commonly affected. Healing partial-thickness burns have been involved in more than 80 percent of reported cases, whereas areas of full-thickness epidermal loss appear to be spared. Infection can lead to rapid desquamation of areas of previous epithelialization, with erosive changes and hemorrhage of burn wounds. A Kaposi's varicelliform-like eruption with vesicles developing around the circumference of the burn wound and subsequent development of erosive lesions has also been described. The outcome of infection has varied considerably with the series. Initial reports3 of death due to visceral HSV involvement of the liver, adrenals, and other organs, or due to secondary bacterial infection, have not been confirmed in more recent experience. Overall, more than 80 percent of described patients have healed lesions in a period ranging from 4 to 28 days. [18] [19] [20] [21] [22] [23] [24] Intravenous acyclovir therapy has been used in about one third of patients and topical therapy has been used in several others, but the lack of controlled trials makes it difficult to assess whether treatment has influenced the healing of lesions. However, the dramatic clinical improvement in some patients following the institution of systemic acyclovir18 and the CHEST / 106 / 1 / JULY, 1994 / Supplement 17S FIGURE 3. This 4-year-old girl was admitted with 50 percent BSA burn and associated inhalation injury. Erosive lesions from which HSV-1 was recovered were noted in the graft donor sites on hospital day 20. She was treated with intravenous acyclovir for 10 days. HSV antibody titers were nonreactive at the time of lesions. data are available to determine whether acyclovir pharmacokinetics are affected, and dose adjustments are required in extensively burned patients.
In summary, relatively few cases of herpetic burn wound infection have been described in the literature, but the usual clinical picture is one of self-limited wound infections occurring several weeks after thermal inijirv. Areas of active enidermal rezenera- extensive experience in mucocutaneous infections of other immunocompromised patients suggest that this intervention speeds healing. Furthermore, Tomford and colleagues25 used intravenous acyclovir in 10 of 30 cases of herpetic burn wound infection and reported prompt responses. In contrast, 4 (22 percent) of 18 patients treated with topical acyclovir failed to respond clinically and had to be switched to intravenous therapy. All patients eventually recovered.
Such experiences indicate that documented HSV burn wound or graft site infection should be treated with systemic acyclovir. Similarly, in patients with clinically apparent recurrent orolabial herpes, systemic acyclovir therapy is indicated if the patient has evidence of contiguous spread to upper respiratory tract, esophagus, or head and neck, and may be prudent if there are significant risk factors for herpetic wound infection. However, the risk of developing burn wound invasion among individuals who have localized orolabial lesions or asymptomatic salivary shedding is not defined. Similarly, a possible role for acyclovir prophylaxis in those who are HSV seropositive and at high risk because of extensive burns, with involvement of the face or neck and/or inhalation injury, would require appropriate clinical trials. No FIGURE 4 . This previously reported'8 32-year-old man was admitted with an 18 percent scald burn of the chest, abdomen, and anterior thighs. Split-thickness skin grafts were placed in the wounds 4 days after admission. Ulcerative lesions positive for HSV-1 were noted in the graft donor sites of the thigh (top) and lower leg (bottom) 24 days following admission. Treatment with intravenous acyclovir led to prompt resolution of a fever, which had been unresponsive to multiple antimicrobics. A fourfold rise in HSV antibody titer from 1:32 to 1:128 occurred. IRetrospective study.
tion, particularly healing partial-thickness burn sites, are typically involved. Intravenous acyclovir treatment has been associated with prompt clinical improvement.
CMV INFECTIONS
Longitudinal surveys have also found high frequencies of laboratory evidence of CMV infection in burn patients (Table 4) 10,15-17,26,27 Serologic evidence for CMV infection has been found in approximately 20 percent to 40 percent of patients in most series. Although less commonly documented, virus recovery from oropharyngeal secretions or urine has been detected in about 30 percent of patients in several studies (Table 4) .10,16 The likelihood of detecting infection depends on multiple factors, including surveillance methods, duration of follow-up, and extent of burn. Up to 85 percent of CMV-seropositive patients with large burns will shed virus if followed up on a sustained basis.10
Cytomegalovirus infection subsequent to burns may be primary, ie, due to exogenous infection of previously uninfected (seronegative) patients, or secondary, ie, due to reactivation of endogenous virus or possible exogenous reinfection in infected (seropositive) patients. Although secondary infections are more common, primary infections have been found in approximately one half of severely burned patients and in about one in five seronegative patients overall (Table 5 ). The risk factors for CMV infection include transfusion of CMV-seropositive blood products, use of skin allografts from CMV-seropositive donors, immunosuppression related to burns and cyclosporine use, extensive (>30 percent BSA) and full-thickness burns, and prolonged hospitalization (>3 weeks).'0"17 44-year-old man with 40 percent BSA burn who developed severe bleeding from rectal ulcers at the time of primary CMV infection. Although cultures from multiple sites, including rectum, were negative, the biopsy specimen showed numerous CMV intranuclear inclusions. In addition, a possible association between CMV infection and bacterial infections in burn patients has been suggested in clinical studies17'30 and animal models.34 To our knowledge, the possible efficacy and tolerability of anti-CMV chemotherapy with ganciclovir or foscarnet have not been described in burn patients.
VARICELLA-ZOSTER VIRUS (VZV) INFECTIONS
Development of varicella in children during treatment for cutaneous burns has been associated with prominent lesions in areas of healing partial-thickness burns and donor sites, perhaps related to unique susceptibility of regenerating epidermal cells.3 In one burn unit outbreak, one index case and all six susceptible contacts aged 1 to 7 years (2 percent to 22 percent BSA) experienced varicella.35 More numerous and deeper lesions, described as punched out, hemorrhagic, and associated with higher rates of secondary infection and scarring, developed in partial-thickness burns and healing donor sites. Losses of some skin autografts but no visceral complications occurred. Weintraub et a135 recommended that susceptible patients should not be admitted to a unit with active varicella cases, that grafting procedures be delayed, if feasible, in patients with active disease until the eruption subsides, and that varicella zoster immune globulin could be considered for prophylaxis in more severely burned susceptible contacts.
More recently, systemic acyclovir therapy, in higher doses than those used for HSV infection, has been found to speed the healing of lesions in varicella of immunocompromised36 and, if initiated within 24 h of rash onset, previously healthy children.37 Oral (20 mg/kg four times daily up to 800 mg per dose) or, in more seriously ill burn patients, intravenous (10 mg/kg/8 h) acyclovir should be administered as soon as possible after lesion onset. Although herpes zoster has been reported in an elderly burn patient,'5 no association has been recognized between burn-related immunosuppression and development of VZV reactivation.
